Having trouble viewing this email? View in your browser.
ESCMID Logo

21 March 2017
WEEKLY NEWS

Dear colleagues,

Submitters of late-breaking abstracts for ECCMID 2017 in Vienna have been notified yesterday. Please check your in-boxes.

Have a look at the German Society of Infectious Diseases (DGI)’s recommendations, which are part of the choosing wisely initiative. The authors of the publication include ECCMID Programme Director Winfried Kern.

Another ESCMID ad-hoc member, ESCMID Guidelines Director William Hope will lead a new Centre for Antimicrobial Pharmacodynamics (CAP) to address antimicrobial drug development challenge at the University of Liverpool. The state-of-the-art research centre, created in partnership with Liverpool School of Tropical Medicine (LSTM) and North Bristol NHS Trust, aims to help accelerate the development of new antibiotics.

You may also be interested in a recent publication by the European Respiratory Society on Anti-infectives and the Lung

The World Health Organization is setting up an interagency coordination group on antimicrobial resistance to provide practical guidance for approaches needed to ensure sustained effective global action to address antimicrobial resistance.

Your ESCMID communications editors

 

Registration is now open for the TAE Trainees Day round-table session

You may reserve your spot at the table of your choice to discuss your career in an informal setting. Twenty expert tables are offered, and places will be filled on a first-come first-served basis.

› Read more
 

CMI highlight: Levofloxacin vs azithromycin to treat Legionella pneumonia

Researchers in Spain assessed how levofloxacin, azithromycin or clarithromycin treatment affected the outcomes of patients with Legionella pneumonia (LP) requiring hospitalization. The primary endpoint of the study was 30-day mortality. Secondary endpoints included time to defervescence, time to achieve clinical stability, length of intravenous (IV) therapy, length of hospital stay, and early mortality (i.e. death from any cause within 48 hours of hospitalization). Overall, no significant differences between levofloxacin and azithromycin treatment were found for most outcomes. Compared to levofloxacin, patients treated with clarithromycin received longer IV antibiotic treatment and had a longer hospital stay.

› Read more
 

ESGAP publishes newsletter on publications, research, events, ECCMID

In the newsletter, the study group for antibiotic policies gives an update on its most recent publications and research projects as well as an overview of its educational and scientific activities, which include sessions at the upcoming ECCMID as well as other educational events.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.